OTCMKTS:RGDXQ - Response Genetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0023 0.00 (0.00 %)
(As of 07/17/2018 06:00 AM ET)
Previous Close$0.0023
Today's Range$0.0023 - $0.0023
52-Week Range$0.0003 - $0.0074
Volume101 shs
Average Volume18,890 shs
Market Capitalization$90,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.05
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Receive RGDXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RGDXQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RGDXQ
CUSIPN/A
Phone323-224-3900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares38,790,000
Market Cap$0.09

The Truth About Cryptocurrencies

Response Genetics (OTCMKTS:RGDXQ) Frequently Asked Questions

What is Response Genetics' stock symbol?

Response Genetics trades on the OTCMKTS under the ticker symbol "RGDXQ."

How were Response Genetics' earnings last quarter?

Response Genetics, Inc. (OTCMKTS:RGDXQ) issued its quarterly earnings results on Tuesday, March, 31st. The medical research company reported ($0.09) EPS for the quarter. The medical research company earned $4.10 million during the quarter. View Response Genetics' Earnings History.

What is the consensus analysts' recommendation for Response Genetics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Response Genetics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Response Genetics' key competitors?

Who are Response Genetics' key executives?

Response Genetics' management team includes the folowing people:
  • Thomas A. Bologna, Chairman of the Board, Chief Executive Officer (Age 66)
  • Kevin Roy Harris, Chief Financial Officer, Vice President (Age 47)
  • Adanech Getachew, General Counsel (Age 37)
  • Kirk K. Calhoun, Lead Independent Director (Age 73)
  • Michael Serruya, Director (Age 51)
  • Sam Chawla, Independent Director (Age 41)
  • David R Schreiber, Independent Director (Age 55)
  • Richard A. van den Broek, Independent Director (Age 49)

Has Response Genetics been receiving favorable news coverage?

News headlines about RGDXQ stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Response Genetics earned a news impact score of 0.09 on Accern's scale. They also assigned news articles about the medical research company an impact score of 47.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Response Genetics?

Shares of RGDXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Response Genetics' stock price today?

One share of RGDXQ stock can currently be purchased for approximately $0.0023.

How big of a company is Response Genetics?

Response Genetics has a market capitalization of $90,000.00.

How can I contact Response Genetics?

Response Genetics' mailing address is 1640 MARENGO ST 7TH FLOOR, LOS ANGELES CA, 90033. The medical research company can be reached via phone at 323-224-3900 or via email at [email protected]


MarketBeat Community Rating for Response Genetics (OTCMKTS RGDXQ)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe RGDXQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGDXQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.